Taligen Therapeutics Calls Down $10 Million
Taligen Therapeutics Inc., an Aurora, Colo.-based drug company focused on modulation and control of the compliment system, has called down a $10 million, milestne-based tranche of its Series B funding round. The company secured $65 million for the round in 2008, and so far has called down around $36 million. Backers include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Ventures.
23 August 2010•2 mins read
